Effect of Enteral Vitamin A on Fecal Calprotectin in Extreme
Vitamin A contains immune-modulating and anti-inflammatory effects. Researchers have examined whether fecal calprotectin is a sign of intestinal inflammation, as a whole, as a supplement to water-soluble vitamin A for preterm newborns.

This was a prospective observational study nested in a randomized, double-blind, placebo-controlled clinical trial investigating enteral vitamin A (5,000 IU/day) for reducing the severity of bronchopulmonary dysplasia (BPD) in extremely preterm infants. Fecal calprotectin levels were measured using enzyme-linked immunosorbent assay after 28 days of Vitamin A or placebo supplementation.

--Fecal calprotectin was measured in 66 infants (Vitamin A: 33, Placebo: 33). The mean (standard deviation) gestational age, birth weight, and factors influencing fecal calprotectin levels were comparable between the vitamin A versus placebo group infants.

--All infants were exclusively fed with mother’s or donor’s human breast milk if mother’s milk was unavailable using a standardized feeding regimen and received prophylactic probiotic supplementation.

--Fecal calprotectin levels were not significantly different between vitamin A (152) and placebo groups (179).

--Two infants in the vitamin A group developed definite necrotizing enterocolitis compared to none in the placebo group. Incidence of BPD at 36 weeks postmenstrual age was similar between the groups.

Conclusively, the fecal calprotectins in extremely preterm newborns were not affected by the enteral supplementation with water-soluble vitamin A.

Source: https://www.karger.com/Article/Abstract/518680